Monoclonal antibody therapy idiotype

Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986 41 572—578. 

Fagerberg J, Frodin JE, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (abl). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy Cancer Immunol Immunother 1994 38 149-59. 

Perosa F, Scudeletti M, Imro MA, Dammacco F, Luccarelli G, Indiveri F. Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases. Clin Exp Rheumatol 1997 15(2) 201-10. 

Conjugated monoclonal antibodies can be used as carriers of toxic therapy, such as radionuclides, (e.g., yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab), cytotoxic drugs, or cell toxins to specific cell targets. They are also being employed to create tumor vaccines by stimulating a host antibody reaction causing the production of anti-idiotype antibodies. 

---